- Home
- KZIA vs GLTO Comparison
KZIA vs GLTO Comparison
Compare KZIA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- GLTO
- Stock Information
- Founded
- KZIA 1994
- GLTO 2011
- Country
- KZIA Australia
- GLTO Denmark
- Employees
- KZIA N/A
- GLTO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- GLTO Health Care
- Exchange
- KZIA Nasdaq
- GLTO Nasdaq
- Market Cap
- KZIA 7.8M
- GLTO 6.5M
- IPO Year
- KZIA 1999
- GLTO 2020
- Fundamental
- Price
- KZIA $1.40
- GLTO $5.10
- Analyst Decision
- KZIA Strong Buy
- GLTO Buy
- Analyst Count
- KZIA 1
- GLTO 1
- Target Price
- KZIA $20.00
- GLTO $10.00
- AVG Volume (30 Days)
- KZIA 5.4M
- GLTO 16.9K
- Earning Date
- KZIA 03-26-2025
- GLTO 03-07-2025
- Dividend Yield
- KZIA N/A
- GLTO N/A
- EPS Growth
- KZIA N/A
- GLTO N/A
- EPS
- KZIA N/A
- GLTO N/A
- Revenue
- KZIA $1,655,324.00
- GLTO N/A
- Revenue This Year
- KZIA $806.89
- GLTO N/A
- Revenue Next Year
- KZIA N/A
- GLTO N/A
- P/E Ratio
- KZIA N/A
- GLTO N/A
- Revenue Growth
- KZIA 248000.00
- GLTO N/A
- 52 Week Low
- KZIA $1.31
- GLTO $4.40
- 52 Week High
- KZIA $15.80
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- KZIA 36.33
- GLTO 47.88
- Support Level
- KZIA $1.34
- GLTO $4.70
- Resistance Level
- KZIA $2.64
- GLTO $5.35
- Average True Range (ATR)
- KZIA 0.24
- GLTO 0.39
- MACD
- KZIA 0.09
- GLTO -0.01
- Stochastic Oscillator
- KZIA 6.69
- GLTO 40.00
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.